NCT07214519

Brief Summary

This community-partnered study examines a technical assistance intervention designed to help permanent supportive housing agencies implement evidence-based practices to prevent tenant overdose and improve tenant health.

Trial Health

63
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
2,940

participants targeted

Target at P75+ for not_applicable

Timeline
46mo left

Started Jul 2027

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

September 24, 2025

Completed
15 days until next milestone

First Posted

Study publicly available on registry

October 9, 2025

Completed
1.7 years until next milestone

Study Start

First participant enrolled

July 1, 2027

Expected
3.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 30, 2030

6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

March 31, 2031

Last Updated

May 6, 2026

Status Verified

May 1, 2026

Enrollment Period

3.3 years

First QC Date

September 24, 2025

Last Update Submit

May 5, 2026

Conditions

Outcome Measures

Primary Outcomes (1)

  • Composite Score of Agency-Level Fidelity to Overdose Prevention Evidence-Based Practices

    Fidelity will be measured as the extent to which an intervention is implemented as intended by researchers; the specific method of measurement will be determined during the trial's preparatory phase, in consultation with multiple stakeholders. The measurement will comprise a composite score of multiple measures.

    Baseline, Month 12 (End of Wave 1), Month 19 (End of Wave 2), Month 26 (End of Wave 3), Month 33 (End of Wave 4)

Study Arms (4)

Wave 1: Control, Intervention, Sustainment

EXPERIMENTAL

Participants at agencies assigned to wave 1 will receive the control condition from months 1-6; intervention for months 6-12; and sustainment from months 12-45.

Behavioral: TA Intervention

Wave 2: Control, Intervention, Sustainment

EXPERIMENTAL

Participants at agencies assigned to wave 2 will receive the control condition from months 1-13; intervention for months 13-19; and sustainment from months 19-45.

Behavioral: TA Intervention

Wave 3: Control, Intervention, Sustainment

EXPERIMENTAL

Participants at agencies assigned to wave 3 will receive the control condition from months 1-20; intervention for months 20-26; and sustainment from months 26-45.

Behavioral: TA Intervention

Wave 4: Control, Intervention, Sustainment

EXPERIMENTAL

Participants at agencies assigned to wave 4 will receive the control condition from months 1-27; intervention for months 27-33; and sustainment from months 33-45.

Behavioral: TA Intervention

Interventions

TA InterventionBEHAVIORAL

Technical assistance (TA) intervention designed to support PSH agencies in sustainably implementing evidence-based practices to reduce tenant overdose and improve tenant health more broadly.

Wave 1: Control, Intervention, SustainmentWave 2: Control, Intervention, SustainmentWave 3: Control, Intervention, SustainmentWave 4: Control, Intervention, Sustainment

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Supportive Housing Agencies/Individuals who Work at Supportive Housing Agencies:
  • Serve at least 40 tenants in New York and/or New Jersey
  • Have a significant concern for overdose (as demonstrated by past year tenant overdose)
  • Be willing to complete all activities required for participation in the trial
  • Tenants who Live in Supportive Housing Agencies:
  • Must live in an enrolled Supportive Housing Agency
  • Must be 18 years and older

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

NYU Langone Health

New York, New York, 10016, United States

Location

MeSH Terms

Conditions

Drug OverdoseSubstance-Related Disorders

Condition Hierarchy (Ancestors)

Prescription Drug MisuseDrug MisuseChemically-Induced DisordersMental Disorders

Study Officials

  • Kelly Doran, MD

    NYU Langone Health

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
SUPPORTIVE CARE
Intervention Model
CROSSOVER
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 24, 2025

First Posted

October 9, 2025

Study Start (Estimated)

July 1, 2027

Primary Completion (Estimated)

September 30, 2030

Study Completion (Estimated)

March 31, 2031

Last Updated

May 6, 2026

Record last verified: 2026-05

Data Sharing

IPD Sharing
Will share

The data that will be shared / made available to the research community resulting from this project includes: analytic summary matrices for focus groups; analytic summary matrices for one-on-one qualitative interviews; deidentified survey data; summary data for analyses using administrative datasets and accompanying code; and all metadata and other documentation. Study data will be available no later than the time of an associated publication or within 3 months following the end of the study, whichever is first. Deidentified data will be made available after completion of a data use agreement (DUA). Data sharing requests will be reviewed by the study PI and study team. The protocol and statistical analysis plan will be posted on Clinicaltrials.gov only as required by federal regulation or supporting awards and agreements.

Shared Documents
STUDY PROTOCOL, SAP
Time Frame
Study data will be available no later than the time of an associated publication or within 3 months following the end of the study, whichever is first.
Access Criteria
Data that has been prepared for public access by the research community will be archived in the NYU Data Catalog, a research data repository maintained by the NYU Langone Health (NYULH) science library, available free to the NYU community and to the public. Data will be made available to qualified researchers who have a research question appropriate to the data. Deidentified data (i.e., not identifiable at an individual or specific PSH agency level) will be made available after completion of a data use agreement (DUA). Data sharing requests will be reviewed by the study PI and study team.

Locations